JenKem Technology provides high quality activated Y-shaped branched polyethylene glycol derivatives (PEGs) with high purity and low polydispersity.
JenKem Technology’s patented Y-shape PEG derivatives, also known as branched PEG derivatives, contain two linear methoxy PEG chains attached to a central active core. JenKem proprietary Y-shape PEGs are more selective than linear PEGs, due to their sterically bulky structure.
JenKem Technology provides Y-shape branched PEG derivatives for amine pegylation (Y-NHS-40K, Y-COOH-40K), thiol pegylation (Y-MAL-40K), and N-terminal PEGylation (Y-AALD-40K and Y-PALD-40K), click chemistry (Y-ALKYNE-40K) and other applications (Y-NH2-40K or Y-FITC-40K). JenKem’s Y-shape PEG derivatives are chemically purified during synthesis and are essentially free of activated bifunctional PEG side products.
JenKem Technology Y-Shaped PEGs with molecular weights and functional groups not listed in our online catalog, may be available by custom synthesis. Please inquire at firstname.lastname@example.org about pricing and availability.ORDER ONLINE
|PEG PRODUCT||SUBSTITUTION||REACTIVITY DETAILS|
|Y-NHS-40K||≥95%||Y-shaped NHS PEG ester. Reactive towards the amino group of lysine(s) on proteins or other biologics. Amine PEGylation with Y-shape PEG NHS can be completed in less than 1hr at pH 7-8. [1-3]|
|Y-COOH-40K||≥95%||Y-shaped Carboxyl PEG suitable for amine PEGylation|
|Y-MAL-40K||≥95%||Y-shaped Maleimide PEG. Thiol reactive PEG [4-6] ; reacts at pH 5.0-6.5|
|Y-AALD-40K||≥95%||Y-shaped Acetaldehyde PEG. N-terminal amine reactive PEG in the presence of a reducing reagent; less reactive but more selective compared to linear PEG aldehydes; reacts at pH 5-8. [7, 8]|
|Y-PALD-40K||≥95%||Y-shaped Propionaldehyde PEG. Reactive PEG for N-terminal amine in the presence of a reducing reagent; less selective but more reactive compared with Y-AALD-40K; reacts at pH 5-8. [7-10]|
|Y-NH2-40K||≥95%||Y-shaped Amine PEG, more reactive towards acylating agents than the hydroxyl group; readily undergoes reductive amination reactions [11-12]|
|Y-FITC-40K||≥90%||Y-shape Fluorescein PEG, suitable for fluorescence monitoring of the PEGylation reaction with Y-shaped PEGs|
|Y-ALKYNE-40K||≥95%||Y-shaped Alkyne PEG is a convenient click PEG reagent for reaction with azide groups|
Other U-shaped Branched NHS PEGs with Stable Linker
|PEG PRODUCT||SUBSTITUTION||REACTIVITY DETAILS|
|MPEG2 LYS NHS Ester
||≥ 95%||MPEG2-LYS-NHS Ester is reactive towards the amino group of lysine(s), or N-terminal amines|
Applications of Y-Shape PEGs for PEGylation:
|Y-shape PEGs for Drug Delivery and Diagnostics||Drug Molecule or Other Entity PEGylated with Y-shape PEG||References|
|Y-shape PEG Amine||Paclitaxel||11|
|Y-shape PEG Maleimide||siRNA||4|
|Cocaine esterase||14, 6|
|Y-shape PEG NHS||Calcium phosphate nanoparticles||15|
|DNA aptamer (SOMAmer)||2|
|LIF receptor antagonist (LA)||21|
|L-RNA (Spiegelmer)||22, 23|
|Y-shape PEG Propionaldehyde||Laccase||10|
|Ubiquitin-derived 77405 protein||7|
1. Guo, L., et al., Application Instructions for Y-NHS-40K for Amine PEGylation, link.
2. Masao, H., et al., Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys, Nucleic Acid Therapeutics, 2015, doi:10.1089/nat.2015.0567.
3. Winship, A.L., Interleukin-11 alters placentation and causes preeclampsia features in mice, Proc Natl Acad Sci U S A., 2015, 112(52):15928-33.
4. Li, H., et al., Dual MMP7-Proximity-Activated and Folate Receptor-Targeted Nanoparticles for siRNA Delivery, Biomacromolecules 2015, 16 (1), p: 192–201.
5. Yu, W., et al., PEGylated recombinant human interferon-ω as a long-acting antiviral agent: Structure, antiviral activity and pharmacokinetics. Antiviral Research, 2014. 108: p. 142-147.
6. Fang, L., et al., Rational design, preparation, and characterization of a therapeutic enzyme mutant with improved stability and function for cocaine detoxification. ACS chemical biology. 2014, 9(8):1764-72.
7. Lorey, S., et al, Novel Ubiquitin-derived High Affinity Binding Proteins with Tumor Targeting Properties, The Journal of Biological Chemistry, 2014, 289,8493-8507.
8. Farkas, T, et al., Additional Studies in the Separation of PEGylated Proteins by Reversed Phase Chromatography, LC/GC, 2008.
9. Liebner, R., et al., Head to Head Comparison of the Formulation and Stability of Concentrated Solutions of HESylated versus PEGylated Anakinra, Journal of Pharmaceutical Sciences 2015, 104(2): 515-526.
10. Mayolo-Deloisa, K., et al., Aldehyde PEGylation of laccase from Trametes versicolor in route to increase its stability: effect on enzymatic activity, Journal of Molecular Recognition 2015, 28(3): 173-179.
11. Amoozgar, Z., et al., Dual-layer surface coating of PLGA-based nanoparticles provides slow-release drug delivery to achieve metronomic therapy in a paclitaxel-resistant murine ovarian cancer model, Biomacromolecules. 2014. 15(11):4187-94.
12. Hoehlig, K., et al., A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis. Mol Ther, 2013. 21(12): p. 2236-46.
13. Hoffmann, S., et al., RNA Aptamers and Spiegelmers: Synthesis, Purification, and Post-Synthetic PEG Conjugation. Current Protocols in Nucleic Acid Chemistry, 2011, 46:4.
14. Narasimhan, D., et al., Subunit Stabilization and Polyethylene Glycolation of CocaineEsterase Improves In Vivo Residence Time. Mol Pharmacol 2011, 80, 1056.
15. Ashokan, A., et al., Multifunctional calcium phosphate nano-contrast agent for combined nuclear, magnetic and near-infrared in vivo imaging. Biomaterials 2013, 34, 7143.
16. Risitano, A.M. ,et al., Peptide inhibitors of C3 activation as a novel strategy of complement inhibitionfor the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123, 2094.
17. Wang, S., et al.,Y-type polyethylene glycol modified G-CSF and preparation method and use thereof. Patent CN200780051378. 2007.
18. Marcus, Y., et al., Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible PEGylation: A Study with Gentamicin. J Med Chem 2008, 51, 4300.
19. Zhou, W., et al., Interferon alpha 2a modified by polyethylene glycol, its synthesis process and application. Patent CN200780050541. 2007.
20. Zhou, W., et al., Interferon alpha 2b modified by polyethylene glycol, its synthesis process and application. Patent CN200780050542. 2007.
21. Menkhorst, E., et al., Vaginally Administered PEGylated LIF Antagonist Blocked Embryo Implantation and Eliminated Non-Target Effects on Bone in Mice. PLoS ONE 2011, 6, e19665.
22. Roccaro, A.M. et al. SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy. Cell Reports 2014, 9, 118.
23. Khan, M.A., et al., Targeting complement component 5a promotes vascular integrity and limits airway remodeling. PNAS 2013, 110, 6061.
24. Zhou, W., et al., Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof. Patent CN200880009718. 2008.
25. ChuanYun, D., et al., Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosisfactor-alpha (TNF-α) against murine fibrosarcoma. Sci China Life Sci 2011, 55, 128.
26. ChuanYun, D., et al., Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α(TNF-α) conjugate for therapeutic application. Sci China Life Sci 2013, 56, 51.
Founded in 2001 by recognized experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to on-site manufacturing from ethylene oxide, enabling facile traceability for GMP regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.